OverviewChartNewsTraderScreen

Morgan Stanley Knock-Out NOVN/  DE000MG2RCT3  /

Stuttgart
06/09/2024  18:46:16 Chg.0.00 Bid22:00:37 Ask22:00:37 Underlying Strike price Expiration date Option type
2.61EUR 0.00% -
Bid Size: -		 -
Ask Size: -		 NOVARTIS N 74.141 CHF 31/12/2078 Call
TeleTrader 18/07 Novartis Q2 EPS up 47% to $1.60
GlobeNewswire 26/06 As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire 13/06 Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
GlobeNewswire 29/05 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
TeleTrader 02/05 Novartis to acquire Mariana Oncology for $1.7B
TeleTrader 23/04 Novartis up 5% on upbeat guidance, earnings
TeleTrader 23/04 Novartis EPS up 28% to $1.31 in Q1
GlobeNewswire 16/04 Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...
TeleTrader 11/04 Novartis launches offer for Morphosys at €68 per share
TeleTrader 09/04 Novartis to reduce workforce by 680 in Product Development
GlobeNewswire 14/03 IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
TeleTrader 12/03 Germany clears Novartis' MorphoSys $2.9B deal
GlobeNewswire 28/02 Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
TeleTrader 05/02 Novartis to acquire MorphoSys for $2.9B
TeleTrader 31/01 Novartis net sales up 8% to $11.4B in Q4
GlobeNewswire 10/01 Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...
GlobeNewswire 05/01 Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...
GlobeNewswire 02/01 Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...
GlobeNewswire 21/12/2023 Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire 19/12/2023 Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, N...
GlobeNewswire 11/12/2023 Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and ...
GlobeNewswire 08/12/2023 Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broa...
GlobeNewswire 06/12/2023 Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement i...
TeleTrader 28/11/2023 Novartis expects 5% annual sales growth until 2027
GlobeNewswire 20/11/2023 Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH